Blog Home Page - SelectION, Inc.

+321 123 4567

info@test.com

User login

Russian Spanish German

Home
About
Technology
Drug Development
News
Contact

About

selectION is developing a new class of medicines to treat autoimmune diseases and other ion channel related disorders.

Recent News

selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease October 21, 2025

Contact

US Headquarters:
selectION, Inc.
655 India Street, Suite 204
San Diego, CA 92101
USA

European R&D Site:
selectION Therapeutics GmbH
Am Klopferspitz 19
82152 Martinsried / Planegg
Germany

info@selectiontherapeutics.com

Copyright © 2017- selectION, Inc. | website by emago.com.

Home
About
Technology
Drug Development
News
Contact